0RC7.L - Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ)
ScheelevAegen 22
Lund 223 63
Sweden
46 46 16 56 70
https://www.hansabiopharma.com
Settore/i:
Settore:
Impiegati a tempo pieno: 159
Figure dirigenziali chiave
| Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
|---|---|---|---|---|
| Mr. Søren Tulstrup M.Sc | Pres & CEO | 15,26M | N/D | 1965 |
| Mr. Donato Spota | CFO & Sr. VP | N/D | N/D | 1971 |
| Dr. Christian Kjellman | Sr. VP, Chief Scientific Officer & COO | N/D | N/D | 1967 |
| Ms. Eva-Maria Joed | VP of Fin. & Admin. | N/D | N/D | 1969 |
| Mr. Klaus Sindahl | VP & Head of Investor Relations | N/D | N/D | N/D |
| Ms. Anne Säfström Lanner | Sr. VP & Chief HR Officer | N/D | N/D | 1969 |
| Mr. Emanuel Björne | VP & Head of Bus. Devel. | N/D | N/D | 1973 |
| Dr. Lena Winstedt | Head of Science | N/D | N/D | 1969 |
| Ms. Vincenza Nigro M.B.A. | VP & Head of Medical Affairs | N/D | N/D | N/D |
| Dr. Achim Kaufhold M.D., Ph.D. | Sr. VP & Chief Medical Officer | N/D | N/D | 1958 |
Descrizione
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Governance aziendale
L'ISS Governance QualityScore di Hansa Biopharma AB (publ) al 1 giugno 2023 è 2. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 5.
